Home » FDA Approves Novartis’ Cosentyx for Axial Spondyloarthritis
FDA Approves Novartis’ Cosentyx for Axial Spondyloarthritis
Novartis’ Cosentyx (secukinumab) has been granted FDA approval for treatment of non-radiographic axial spondyloarthritis (nr-axSpA), a form of arthritis that can cause inflammation on the spine.
The approval was based on the results of a phase 3 trial in which Cosentyx, a human monoclonal antibody, demonstrated significant improvements vs. a placebo.
The European Medicines Agency had approved Cosentyx for the same indication in April.
Upcoming Events
-
07May
-
14May
-
30May